Literature DB >> 24372587

Reliability of histological malignancy grade, ER and HER2 status on core needle biopsy vs surgical specimen in breast cancer.

Helga D Munch-Petersen1, Birgitte B Rasmussen, Eva Balslev.   

Abstract

Early determination of malignancy grade and biomarkers in primary breast cancer is important when planning the treatment with neoadjuvant therapy and breast-conserving surgery. The aim of this study was to assess the reliability of malignancy grade on core needle biopsies, and to compare the concordance of ER and HER2 status on core needle biopsies vs surgical specimens. Eighty-nine patients with invasive ductal or lobular carcinoma were included. Malignancy grade was upgraded by one degree in 23.0%. The mitotic count had most impact on the malignancy grade, and may be underestimated on core needle biopsies compared with surgical specimens. ER status was concordant in core needle biopsies and surgical specimens in 98.0%, but should be repeated when doubtfully negative. HER2 status was concordant in 84.0% prior to FISH-HER2. Including FISH-HER2 data, the core needle biopsies showed a final total concordance of 95.4%. In conclusion, ER and HER2 are useful markers in core needle biopsies, providing a reliable base for preoperative decisions in neoadjuvant chemotherapy, and may be omitted on surgical specimens with certain precautions and exceptions. Determination of malignancy grade should be repeated on surgical specimens, and one should be aware of underestimation on core needle biopsies.
© 2013 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  HER2; breast cancer; core needle biopsy; estrogen receptor; malignancy grade

Mesh:

Substances:

Year:  2013        PMID: 24372587     DOI: 10.1111/apm.12213

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  5 in total

1.  Utility of Human Epidermal Growth Factor Receptor 2 (HER2) Retesting of Histologic Grade 3 Invasive Breast Carcinomas.

Authors:  Rebecca Gologorsky; Elizabeth Cureton; Veronica Shim
Journal:  Perm J       Date:  2019

2.  Comparison of Core Needle Biopsy and Excision Specimens for the Accurate Evaluation of Breast Cancer Molecular Markers: a Report of 1003 Cases.

Authors:  Jie Chen; Zu Wang; Qing Lv; Zhenggui Du; Qiuwen Tan; Di Zhang; Bingjun Xiong; Helin Zeng; Juxiang Gou
Journal:  Pathol Oncol Res       Date:  2017-01-10       Impact factor: 3.201

3.  Preoperative Ultrasound-guided Sub-areolar Biopsy in Predicting Occult Nipple Involvement in Breast Cancer Patients: Proposal for a Methodological Approach.

Authors:  Vittorio Altomare; Paolo Orsaria; Antonella Grasso; Lorenza Caggiati; Edy Ippolito; Francesco Pantano; Matteo Sammarra; Carlo Altomare; Giuseppe Perrone; Gabriella Gullotta; Rita Carino
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

4.  Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.

Authors:  Vassiliki Kotoula; Mattheos Bobos; Zoi Alexopoulou; Christos Papadimitriou; Kyriaki Papadopoulou; Elpida Charalambous; Eleftheria Tsolaki; Grigorios Xepapadakis; Irene Nicolaou; Irene Papaspirou; Gerasimos Aravantinos; Christos Christodoulou; Ioannis Efstratiou; Helen Gogas; George Fountzilas
Journal:  PLoS One       Date:  2014-08-06       Impact factor: 3.240

5.  A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer.

Authors:  Sirwan M Hadad; Lee B Jordan; Pankaj G Roy; Colin A Purdie; Takayuki Iwamoto; Lajos Pusztai; Stacy L Moulder-Thompson; Alastair M Thompson
Journal:  BMC Cancer       Date:  2016-09-22       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.